Uqora Active and Upcoming Clinical Research

Active: Uqora and Urinary Health in Women with Recurring UTI

Study title: Evaluation of the Impact of the Uqora Dietary Supplement Products on Urinary Tract Infection (UTI) Incidence in Women With Recurring UTIs.

Study overview: The present study seeks to evaluate the impact on Uqora’s products on UTI recurrence in females who have been treated with antibiotics for 2 or more UTIs in the past 6 months. Subjects will be randomized into 1 of 3 groups and will take the study product daily for 180 days. Subjective data and compliance will be reported weekly. UTI incidence will be recorded monthly. UTI is defined as receiving antibiotic treatment from a healthcare practitioner. The study groups will be statistically compared. For more information, visit Uqora's Study Record.

Study type: Randomized, double-blind, placebo-controlled, human subject clinical trial.

Number of subjects: 360 total subjects; 120 subjects per group.

Study period: 6 months

Study subjects: Females aged 18+ with recurring UTIs (2 or more in the past 6 months)

Study groups:

1) placebo capsules + placebo drink-mix

2) placebo capsules + active drink-mix

3) active drink-mix + active capsules

Study endpoints: Time to UTI recurrence, UTI frequency, percentage of subjects without UTI recurrence, subjective urinary health and quality of life questionnaires.

Start date: August, 2019

Projected completion date: August, 2020

Study location: United States

Principal Investigator: Martina Speight, NP – Stanford Health Care

Research partner: This study is being coordinated by Hawthorne Effect, Inc., a contract research organization based in Lafayette, CA. Hawthorne Effect addresses subject recruitment, engagement, retention, protocol adherence, and high-quality data collection that is HIPAA-compliant and adheres to strict clinical trial conduct guidance such as GCP, ISO 14155 and other international clinical trial quality guidelines. Founded in 2014, Hawthorne Effect has performed a range of trials, including sponsor regulated clinical trials, investigator-led academic population studies in urban and remote communities, and validation of contemporary health innovation platforms through collaboration with academic and clinical institutions and healthcare start-ups around the US. Clients include Stanford University, University of Pennsylvania, Northwestern University, Mount Sinai Medical School, Medstar, Cedars Sinai, Abbott, Edwards Lifesciences, Omada Health, QBio, and others. 

Uqora UTI Prevention Clinical Trial

 

Upcoming: George Washington University Urology Clinical Trial on Uqora in Women with Recurring UTIs

Location: George Washington University Medical Faculty Associates Urology Clinic, Washington D.C.

Principal Investigator: Dr. Michael Hsieh MD, PhD – Director of Research at Children’s National Hospital, Director of the Clinic for Adult and Adolescent Pediatric Onset Urology, Associate Professor at George Washington University.

Study overview: Subjects that meet the criteria will take placebo or active study product once daily for 12 months. The primary study outcome will be frequency of recurrent cystitis episodes over 12 months, defined as the presence of at least 1 UTI symptom (dysuria, frequency, urgency, and/or suprapubic pain) plus at least 103 CFU/mL uropathogens in a midstream urine culture.

Study type: Randomized, double-blind, placebo-controlled, human subject clinical trial.

Number of subjects: 240 total subjects; 120 subjects per group

Study subjects: Women will be eligible for the study if they are at least 18 years of age, in good general health, no active cancer or immunosuppression, have no current UTI symptoms, reported at least 3 symptomatic episodes of cystitis in the past year resulting in a visit to a clinician (documentation required), at least 1 episode of which needs to be culture confirmed (≥103 colony-forming units [CFU]/mL bacteria in a voided midstream urine culture).

Uqora clinical research on recurrent uti in women

 

Upcoming: Rush University Medical Center Clinical Trial in Women with Recurring UTIs 

Location: Rush University Medical Center Obstetrics and Gynecology, Chicago, IL.

Principal Investigator: Dr. Kristin Jacobs MD – Department of Obstetrics and Gynecology, Division of Female Pelvic Medicine and Reconstructive Surgery at Rush Medical College.

Study overview: In development.

uqora for uti prevention

 

If you’d like to be kept informed about future trials, add your email to the "Stay in touch" box below.

If you’re a researcher and would like to collaborate on future research, please contact us here.

Add feminine cleansing wipes for just $5.99

Stay fresh while keeping your pH balanced. Each pack includes 20 wipes. Learn more.

pH-balanced

Hypoallergenic

Biodegradable

This is for you if:
You want to stay fresh and maintain a healthy pH.

How does it work?
As you know, hygiene is a key part of UTI prevention. But not all wipes are created equal. Some can mess with your body’s natural chemistry and do more harm than good. Our wipes keep you clean, fresh, and balanced — without any nasty ingredients.

Directions: 
Use any time you want to freshen up. That might be after sex, exercise, long plane rides — you know your body better than anyone.

Free of:
Allergens, alcohol, parabens, sulfates, sulfates, dyes, phthalates, chlorine bleach.

Ingredients:
Water, triethyl citrate, sodium benzoate, allantoin, lactic acid, carprylyl/capryl glucoside, glycerin, fragrance, sodium dehydroacetate, tetrasodium EDTA, citric acid, aloe barbadensis leaf juice, vaccinium macrocarpon fruit extract, calendula officinalis flower extract, sodium citrate, potassium sorbate.

Spin to win